The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study  by Faxon, David P et al.
CLINICAL STUDIES Acute Myocardial Infarction
The Effect of Blockade of the CD11/CD18 Integrin
Receptor on Infarct Size in Patients With Acute
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OBJECTIVES The purpose of this study was to determine whether Hu23F2G (LeukoArrest), an antibody
to the CD11/CD18 integrin receptors, would reduce infarct size in patients undergoing
primary angioplasty for an acute myocardial infarction.
BACKGROUND Reperfusion injury in acute myocardial infarction has been shown experimentally to be related
to neutrophil accumulation. Inhibitors of the CD11/CD18 or CD18 integrin receptors have
been shown to reduce infarct size in experimental models.
METHODS Patients within 6 h of onset of chest pain with ST-segment elevation were randomized to
receive either 0.3 mg/kg or 1.0 mg/kg of Hu23F2G or placebo just before angioplasty of
occluded arteries (Thrombolysis in Myocardial Infarction TIMI flow grade 0 or 1). The
primary end point was infarct size as measured by sestamibi single-photon emission computed
tomography (SPECT) scan five to nine days later.
RESULTS Four-hundred and twenty patients were enrolled and received a placebo or the study drug.
The groups did not differ in baseline or angiographic characteristics or angioplasty results.
Infarct size was 16%, 17.2% and 16.6%, for placebo, 0.3 mg/kg and 1.0 mg/kg, respectively,
of the left ventricle (p  NS). No differences were evident in those patients with anterior
myocardial infarction or those presenting within 2 h of onset of chest pain. Corrected TIMI
frame count was also not different between groups. Clinical events at 30 days were very low,
with a mortality of 0.8%, 1.4% and 3.3%, respectively. The drug was well tolerated, with a
slight increase in minor infections in the high dose group.
CONCLUSIONS The results of this multicenter, double-blind, placebo-controlled, randomized clinical trial
demonstrated that an antibody to CD11/CD18 leukocyte integrin receptor did not reduce
infarct size in patients who underwent primary angioplasty. (J Am Coll Cardiol 2002;40:
1199–204i) © 2002 by the American College of Cardiology Foundation
Reperfusion therapy reduces infarct size, but reperfusion
injury may limit its benefits (1–8). Experimental studies
have demonstrated that the inhibition of the CD11/CD18
leukocyte integrin receptor can result in a significant reduc-
tion of infarct size (9–14). In addition, inhibition can
improve endothelial function, coronary blood flow and left
ventricular hemodynamics. Hu23F2G (LeukArrest) is a
humanized antibody directed against all isoforms of the
CD11/CD18 integrin receptor (15). It has been shown to
inhibit the attachment and transmigration of neutrophils, as
well as adhesion-mediated release of oxygen-free radicals in
vitro (oral communication, ICOS Corp., October 1997).
This multicenter, randomized, double-blind study was
undertaken to evaluate the safety and efficacy of Hu23F2G
in reducing infarct size as determined by sestamibi single-
photon emission computed tomography (SPECT) scanning
in patients with ST-segment elevation acute myocardial
infarction (MI) undergoing primary angioplasty.
METHODS
This study was conducted at 54 study centers in the U.S.
that were capable of performing primary angioplasty (see
complete Appendix 1 online at www.cardiosource.com/
jacc.html). Patients were eligible for participation if they
were between the ages of 18 and 85, had chest pain or other
typical signs or symptoms of acute MI of less than 6 h in
duration and were candidates for primary angioplasty. For
anterior MI, the electrocardiogram (ECG) entry criteria
were ST-segment elevation of at least 2 mm in at least two
contiguous precordial leads or new left bundle branch block.
For inferior MI, the ECG entry criteria were at least 1-mm
ST-segment elevation in two or more inferior limb leads (II,
III, AVF), with reciprocal ST depression of at least 0.5 mm
in two or more precordial leads. Patients were excluded if
they had a history and ECG evidence of previous Q-wave
MI or an ECG pattern that made the diagnosis of MI
difficult. Other exclusion criteria were cardiogenic shock,
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treatment with thrombolytic therapy before study drug
administration, a baseline serum creatinine of 2 mg/dl,
evidence of an ongoing bacterial infection, pregnancy and
the presence of other serious medical conditions.
After informed consent, patients were randomized into
the study and then immediately taken to the cardiac
catheterization laboratory, where coronary angiography was
performed and Thrombolysis In Myocardial Infarction
(TIMI) flow grade determined. The infarct-related artery
was initially injected to determine TIMI flow just before the
administration of the study drug (16). Subsequently, mul-
tiple views of both coronary arteries were obtained after
intracoronary nitroglycerin administration. Care was taken
to ensure that the entire vessel and catheter was visualized to
calculate TIMI frame count. If the infarct artery showed
TIMI 0 or 1 flow grade, the patient was enrolled into the
study. Patients who showed TIMI 2 or 3 flow grade did not
receive the study drug but had complete screening data
obtained. The study drug was administered as a weight-
adjusted, intravenous bolus over 1 to 2 min. Patients were
randomized to receive either 0.3 mg/kg or 1 mg/kg of
Hu23F2G IV or placebo. Previous studies in normal vol-
unteers have shown that these doses resulted in an 80%
saturation of the CD11/CD18 receptor for 12 to 24 h.
These doses, however, were lower than those shown to be
neuroprotective in experimental studies (that is, 4 mg/kg).
All patients received aspirin and heparin that was adminis-
tered by intravenous infusion to maintain the activated
clotting time between 250 and 300 s. Angiography was
performed using standardized techniques of angioplasty
with initial passage of a guidewire and balloon dilation. The
use of glycoprotein IIb/IIIa antagonists was permitted, as
was the use of coronary stents or other devices, at the
discretion of the operator. Only the infarct-related artery
was treated.
After the procedure, the sheaths were removed. The
patients were then treated in the Coronary Care Unit. The
institution of angiotensin-converting enzyme inhibitors,
beta-blockers and platelet antagonists such as ticlopidine or
clopidogrel were used at the discretion of the investigator.
Five to nine days after the administration of the study
drug, a technetium-99m sestamibi SPECT image was
obtained. Patients were discharged from the hospital, and
they returned for an outpatient visit at 30 days for clinical
assessment and determination of adverse events. At 6
months, the patients were contacted by telephone to deter-
mine their vital status and the need for rehospitalization and
follow-up procedures.
Nuclear imaging technique. The nuclear core laboratory
(Mayo Clinic Foundation, Rochester, Minnesota) initially
validated adequate image quality at each site using a cardiac
phantom and a quality control test (17). Those centers with
single-headed cameras were required to use either a step-
and-shoot mode or a continuous mode in circular orbit.
Thirty images were required in a 64-  64-word mode
matrix over a 180° arc, beginning at 45° right anterior
oblique and ending in the left posterior oblique position,
with an image time of greater than 40 s. For multihead
SPECT systems, acquisition was performed over 360° every
6°. Data were stored in 64- 64-word mode matrix with an
image time of greater than 30 s. Raw unprocessed data, the
most recent 30 M count flood images and the most recent
center of rotation study were forwarded to the core labora-
tory, which was blinded to treatment assignment. Measure-
ment of infarct size has been described and validated
previously (17–19). Quantitation of the extent of left ven-
tricle with absent perfusion was performed using a five-slice
technique, with short axis slices obtained every 6 mm.
Quantitation was performed using threshold techniques and
standard geometrical formulas. Infarct size was expressed as
the percent of left ventricle with a perfusion defect.
Core angiographic laboratory. The core angiographic lab-
oratory (University of Washington, Seattle) blindly re-
viewed all angiograms. The TIMI flow and corrected TIMI
frame counts were determined as previously defined (16).
Quantification of the coronary stenoses was performed by
two readers who had no knowledge of the treatment
assignment. Collaterals to the infarct-related artery were
graded as present or absent. If present, the degree of
perfusion was graded as full if the entire vessel was visual-
ized and partial if only a portion of the vessel was visualized.
Safety monitoring. A safety summary was faxed to the
coordinating center on day 9 or at hospital discharge. An
Independent Data and Safety Monitoring Committee pe-
riodically reviewed the status of the trial.
Statistical analysis. The sample size was calculated to
detect a reduction in infarct size of 8.5% of the left ventricle
in patients with anterior MI and a reduction of 3.3% in
patients with inferior MI. Using the variability reported
elsewhere for similar patients (18,19), 112 patients per
treatment group were required for two-sided p value of
0.05 at 80% power. Assuming the loss of patients during
the study, 140 patients per treatment group were random-
ized.
The primary analyses were performed using the intention
to treat the population; the results were also analyzed
according to the treatment they actually received. Analyses
of variance was used for comparing baseline characteristics
across groups for continuous variables. The Fisher exact test
was used for comparing treatment groups for categorical
variables.
For the primary efficacy end point, myocardial infarct
Abbreviations and Acronyms
CK-MB  creatnine kinase-MB fraction (primarily in
cardiac muscle)
ECG  electrocardiogram
MI  myocardial infarction
SPECT  single-photon emission tomography
TIMI  Thrombolysis In Myocardial Infarction
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size, determined by technetium-99m sestamibi SPECT
imaging, was compared using analysis of co-variance. The
following variables were used as covariates: area under the
curve for the first 6 h of creatine kinase-MB fraction
(CK-MB), time between initial symptoms and first balloon
deflation, age, gender, pretreatment TIMI flow and infarct
location. The primary analysis used imputed values for
missing data. Patients who died before imaging (n  8)
were assigned the largest infarct size measured for that
infarct location (anterior or other) for each patient. For
patients who were alive but who did not obtain a follow-up
SPECT image (n  22), the median value measured for
each infarct location was used. A Cox proportional hazards
regression model was used for the survival analysis.
RESULTS
Patient population. Six-hundred and thirty-seven patients
were randomized and 420 patients with TIMI flow grade 0
or 1 flow were enrolled. One-hundred and sixty-nine
patients of 214 did not receive study drug because of their
TIMI 2 or 3 flow grade at initial angiography. One hundred
and twenty-eight received 0.3 mg/kg of LeukoArrest, 139
patients received 1 mg/kg of LeukoArrest and 157 patients
received placebo. The follow-up was complete at 30 days in
99% of patients. Fourteen patients (seven from the placebo
group) received a different therapy than initially assigned.
Baseline characteristics. The baseline demographic and
clinical characteristics of the 420 patients enrolled were not
different between groups receiving the study drug versus the
placebo (Table 1). Medication use during hospitalization
was not different between groups. The angiographic find-
ings showed the infarct artery to be the left anterior
descending in 33% to 36% (Table 2). TIMI 0 or 1 flow
grade was confirmed by subsequent core angiographic lab
assessment in 96% to 98% of patients. Collateral vessels
were present to the infarct related artery in 32% to 40% of
patients. Full collateralization was present in 29% to 37%
percent of those who had collaterals.
Angioplasty results. A successful procedure, defined as less
than a 50% residual stenosis without death or emergency
bypass surgery, was seen in 86% to 89% of each group
(Table 2). Stents were placed in 85% of patients and
abciximab was used in 65% to 73% of patients. The residual
stenosis was less than 9% in all three groups; TIMI 3 flow
grade was established in 81% to 86% of patients. None of
the differences among the three groups were statistically
significant.
Infarct size. The final infarct size for the intention-to-treat
population, with and without imputation, is shown in
Figure 1A and 1B. Including imputed values for missing
data, infarct size was 16%, 17.2% and 16.6% of the left
ventricle for placebo, 0.3 mg/kg and 1 mg/kg, respectively
(p  0.796). The observed data (without imputation) on
390 patients (92.9% of the study group) gave similar results.
The subgroup of patients with anterior MI had signifi-
cantly greater infarct size (averaging 25%), but again no
differences were noted among the three groups. Likewise,
when patients were subdivided by the time from the onset of
chest pain to balloon deflation or by the presence of
collaterals, there were no differences. Infarct size, measured
by CK-MB area under the curve for 24 h, was not different
among the three groups (175%, 175% and 184% per hour
for placebo, 0.3 mg/kg and 1 mg/kg, respectively). Micro-
vascular flow, assessed by corrected TIMI frame counts,
were also not different among the groups (21.3%, 23.2% and
22.3%, respectively).
Table 1. HALT-MI: Demographics and Baseline
Characteristics
Hu23F2G
0.3 mg/kg
(n  128)
1 mg/kg
(n  139)
Placebo
(n  153)
Mean age (yrs) 60.4 59.8 60.2
Percent male 73 74 69
Caucasian (%) 89 83 85
Infarct location
Anterior (%) 33 36 34
Inferior/other (%) 67 64 66
Mean time chest pain
to hospital (h)
1.66 1.70 1.71
Mean time chest pain
to balloon (h)
3.9 3.7 3.7
Medical history
Prior MI (%) 13 12 13
Hypertension (%) 50 48 48
Hypercholesterolemia (%) 44 35 44
Cigarette smoker (%) 67 78 67
Prior stent placement (%) 3 3 5
Prior PTCA/atherectomy (%) 9 7 12
Prior CABG (%) 9 4 3
Diabetes (%) 20 17 17
CABG  coronary artery bypass grafting; MI  myocardial infarction; PTCA 
percutaneous transluminal coronary angioplasty.
Table 2. HALT-MI: Angiographic and Angioplasty Results
Hu23F2G
0.3 mg/kg
(n  128)
1 mg/kg
(n  139)
Placebo
(n  153)
Infarct vessel
LAD (%) 34 36 34
Circumflex (%) 14 13 9
RCA (%) 52 51 57
TIMI flow pre-PTCA (%)
0–1 98 96 96
2 2 4 3
Collaterals to IRA (%) 32 42 41
Angiographic success 88 86 89
Percent residual stenosis 8 6 8
TIMI flow-post (%)
0–1 6 6 4
2 9 4 8
3 81 86 86
Corrected TIMI frame count 21.3 23.3 22.3
IRA  infarct-related artery; LAD  left anterior descending; MI  myocardial
infarction; PTCA  percutaneous transluminal coronary angioplasty; TIMI 
Thrombolysis In Myocardial Infarction.
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Clinical events at 30 days. The incidence of major clinical
events was very low, with only eight deaths in the study
population, for an overall 30-day mortality of 1.9% (Table
3). Although there were fewer deaths and reinfarctions in
the low dose group (0.3 mg/kg) and survival at 30 days
tended to be better in the treatment groups, there was no
significant statistical difference (p  0.20), given the low
number of events. When a composite end point using death,
new MI, rehospitalization for heart failure and infarct size
by SPECT scanning were used, no differences between
groups could be discerned.
Adverse events. Major infections occurred in 5% to 10% of
patients, with minor infections in 2% to 9%. The most
frequent infection was urinary tract infection, which oc-
curred in 6.3%, 9.4% and 2.6% of patients in the 0.3 mg/kg,
1 mg/kg and placebo group, respectively. Infections were
more common in the active treatment group but were easily
managed and caused no serious adverse events.
DISCUSSION
The results of this multicenter, randomized, double-blind,
placebo-controlled, parallel group study demonstrated that
Hu23F2G, an antibody directed against the leukocyte
CD11/CD18 integrin receptor, did not significantly reduce
infarct size, as determined by Tc-99m sestamibi SPECT
scanning five to nine days after primary angioplasty. The
drug was well tolerated in this study population, although
infections were slightly more common in the high dose
group.
Neutrophils in reperfusion injury. Reperfusion of isch-
emic myocardium, particularly with oxygenated perfusate,
has been shown to contribute to further tissue damage and
has been called reperfusion injury (4–8). A number of
mechanisms have been proposed for reperfusion injury,
including an excess release of oxygen free radicals. Inflam-
mation during acute MI has been recognized for more than
60 years (20). Experimental and clinical studies have dem-
onstrated an increase in neutrophil accumulation in the
infarct zone upon reperfusion, with an increase in cytokine
release and expression of the CD11/CD18 integrin recep-
tors on white cells (21–24) before, but particularly after,
reperfusion, with the plugging of small arterioles and
capillaries (25). Clinical estimation of microvascular flow
after reperfusion using the rate of resolution of ST-segment
changes, corrected TIMI frame count, or the density of
myocardial contrast has identified patients at higher risk for
subsequent cardiovascular events (26–28).
Inhibitors of the CD11/CD18 integrin receptor. Anti-
bodies to either all or one of the four isoforms of the
CD11/CD18 integrin receptor have been shown to reduce
infarct size, improve coronary blood flow, improve left
ventricular function and decrease neutrophil infiltration
(9–14).
Hu23F2G (LeukArrest), a humanized antibody against
all four leukocyte integrins, has been shown to inhibit
leukocyte attachment and transmigration (15). In normal
volunteers, a greater than 80% saturation of the CD11/
CD18 neutrophil receptor inhibited chemotaxis of granu-
locytes using a skin chamber (personal communication,
ICOS Corp.). In a pilot study of 60 patients undergoing
primary angioplasty with acute MI, using the same doses as
used in this study, an 80% saturation of the receptor was
demonstrated from 24 to 48 h (29). Given the negative
results of this study, it is possible that this degree of
saturation of neutrophil CD11/CD18 receptors is insuffi-
cient to reduce infarct size. It is possible that the use of GP
IIb/IIIa agents in this study may have influenced the results.
Some studies have suggested that abciximab inhibits the
Figure 1. (A and B) HALT-MI infarct size by single-photon emission
computed tomography, imputed values and observed data. LV  left
ventricular.
Table 3. HALT-MI: Clinical and Adverse Events at 30 Days
Event
Hu23F2G
0.3 mg/kg
(n  128)
1 mg/kg
(n  139)
Placebo
(n  153)
Clinical events
Death (%) 0.8 1.4 3.3
Reinfarction (%) 0.8 2.9 3.9
New CHF (%) 1.6 1.4 3.3
Revascularization (%) 12.5 17.3 10.5
Rehospitalization (%) 8.6 10.1 13
Adverse events
Major infection (%) 6 10 5
Minor infection (%) 5 9 2
Bleeding (%) 16 17 15
CHF  congestive heart failure.
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MAC-1 receptor, and this may have similar effects to
LeukArrest (30). The results of the Limitation of Myocar-
dial Injury following Thrombolysis in Acute Myocardial
Infarction (LIMIT AMI) trial, which used an antibody
against the CD18 receptor in patients with acute MI
receiving thrombolysis, also failed to show a significant
difference in infarct size as measured by Tc-99m sestamibi
or TIMI flow (31).
Other agents to reduce reperfusion injury. Clinical trials
of many other agents directed toward reducing reperfusion
injury have been similarly disappointing. Prostacyclin, fluo-
sol, magnesium, poloxmer 188 (rheothrx) and tremetazidine
have also failed to reduce infarct size in randomized clinical
trials (32–34) (M. Marzilli, unpublished data). In contrast,
adenosine has shown promise (35,36). Adenosine is a
potent vasodilator that also has cardioprotective properties,
most likely through the replenishment of high-energy
phosphate stores, inhibition of oxygen-free radicals, inhibi-
tion of neutrophils and improvement of microvascular flow
and ischemic preconditioning (36). The Acute Myocardial
Infarction Study of Adenosine (AMISTAD) study showed
a 33% reduction in infarct size, particularly in patients with
anterior MI (15% vs. 45.5%), when given to patients at the
time of thrombolysis (35). In contrast to the AMISTAD
study, this study had a very low incidence of complications
and death. This could be due to the effectiveness of primary
angioplasty in the treatment of acute MI and/or other
variables, such as patient selection. Although the sites
chosen to participate in the study had considerable clinical
experience in primary angioplasty, the majority were not
academic medical centers. Therefore, the results are likely to
reflect the contemporary practice of primary angioplasty in
patients with their first ST elevation infarction.
Study limitations. This study was sized to demonstrate a
decrease in infarct size of 8.5% of the left ventricle in
anterior MI and a decrease of 3.2% in inferior MI. The
design assumptions were fairly well satisfied, with an 80%
power. However, the study was underpowered to detect a
smaller degree of benefit. Because the area at risk was not
measured, it is possible that measurement of myocardial
salvage would have been a more sensitive measure than final
infarct size. Previous studies, however, have shown a close
relationship between the two (18), and the logistical issues
led to the decision not to determine myocardial salvage. The
dose was chosen to insure at least 80% granulocyte receptor
saturation for 12 to 24 h, which in Phase 1 studies in normal
volunteers resulted in a significant inhibition of chemotaxis,
using a skin window study. However, the dose of drugs and
the timing of administration may not have been sufficient to
inhibit the intense neutrophil accumulation known to occur
during acute MI. Experimental studies have shown that
higher doses are necessary to demonstrate neuroprotection.
Although infarct size has been established as a surrogate end
point for acute MI trials (19), it is possible that the therapy
might have clinical benefits independent of infarct size,
which might have been detected in a much larger trial using
clinical end points.
Conclusions. The results of the multicenter, randomized
trial demonstrate that an antibody to the CD11/CD18
leukocyte integrin receptor did not reduce infarct size in
patients undergoing primary angioplasty. Ongoing studies
of other leukocyte integrin receptor blockers will help to
better define the role of neutrophil inhibition in reducing
infarct size.
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